Characterization of Differentially Detectable Mycobacterium tuberculosis in the Sputum of Subjects with Drug-Sensitive or Drug-Resistant Tuberculosis before and after Two Months of Therapy

Characterization of Differentially Detectable Mycobacterium tuberculosis in the Sputum of Subjects with Drug-Sensitive or Drug-Resistant Tuberculosis before and after Two Months of Therapy.Zainabadi K, Walsh KF, Vilbrun SC, Mathurin LD, Lee MH, Saito K, Mishra S, Ocheretina O, Pape JW, Nathan C, Fitzgerald DW.Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0060821. doi: 10.1128/AAC.00608-21. Epub 2021 Jul 16.PMID: 34060896 Free article.

In Vitro Perspective on What Individual Antimicrobials Add to Mycobacterium avium Complex Therapies

MycobacteriologyResearch Article16 July 2021An In Vitro Perspective on What Individual Antimicrobials Add to Mycobacterium avium Complex Therapies

• Vidhisha V. Sonawane,
• Mike M. Ruth,
• Lian J. Pennings,
• Elin M. Svensson,
• Heiman F. L. Wertheim,
• Wouter Hoefsloot, and
• Jakko van Ingen

https://doi.org/10.1128/AAC.02730-20For Mycobacterium avium complex pulmonary disease (MAC-PD), current treatment regimens yield low cure rates. To obtain an evidence-based combination therapy, we assessed the in vitro activity of six drugs, namely, clarithromycin (CLR), rifampin (RIF), …

Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Tria

Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial.Wasserman S, Davis A, Stek C, Chirehwa M, Botha S, Daroowala R, Bremer M, Maxebengula M, Koekemoer S, Goliath R, Jackson A, Crede T, Naude J, Szymanski P, Vallie Y, Moosa MS, Wiesner L, Black J, Meintjes G, Maartens G, Wilkinson RJ.Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0014021. doi: 10.1128/AAC.00140-21. Epub 2021 Jul 16.PMID: 33972248 Free PMC article.